Alana Keller, OD
Optometrist · Wildwood, MONPI 1558526301
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Sight Sciences, Inc. accounts for 91.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $46,114 and has fallen 97.2% since, to $1,303 in 2025. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $278.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$86K
- Coopervision Inc.$2K
- Oyster Point Pharma, Inc.$1K
- Bausch & Lomb Americas Inc.$814
- Sun Pharmaceutical Industries Inc.$637
- Alcon$606
- plus $2K from 12 others
What the payments were for
- Consulting fees$39,50042%
- Speaking & faculty fees$44,99948%
- Travel & lodging$2,1582%
- Food & beverage$7,3958%
- Education$180%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 102 | $86,497 |
| Coopervision Inc. | 24 | $2,122 |
| Oyster Point Pharma, Inc. | 40 | $1,120 |
| Bausch & Lomb Americas Inc. | 39 | $814 |
| Sun Pharmaceutical Industries Inc. | 26 | $637 |
| Alcon | 21 | $606 |
| Harrow Eye, LLC | 23 | $529 |
| AbbVie(2 entities) | 21 | $490 |
| Dompe US, Inc. | 5 | $321 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $241 |
| Novartis | 12 | $188 |
| Sanofi | 1 | $151 |
| Tarsus Pharmaceuticals, Inc. | 5 | $146 |
| Menicon America Inc | 2 | $80 |
| LKC Technologies, Inc. | 1 | $59 |
| Shire North American Group Inc | 2 | $46 |
| Astellas Pharma US Inc | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TearCare SmartLid$44,955
- TEARCARE(TM) (2.2) SYSTEM KIT$44,955
- TEARCARE SYSTEM$40,545
- MiSight Contact Lens$1,421
- OMNI(R) SURGICAL SYSTEM (US)$350
- Oxervate$246
- SARCLISA$151
- TOTAL30$134
- INFUSE$125
- VUITY$115
- VEVYE$115
- CEQUA$103
How this compares
$94,089 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 43 | $33,222 |
| XdemvyLotilaner | 17 | $31,759 |
| TyrvayaVarenicline Tartrate | 47 | $30,220 |
| CequaCyclosporine | 18 | $10,267 |
| LumiganBimatoprost | 14 | $3,589 |
| Timolol Maleate | 12 | $1,311 |
| Prednisolone Acetate | 25 | $661 |
| Doxycycline Hyclate | 27 | $582 |
| Latanoprost | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $490 | $36,81157 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $146 | $31,75917 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,120 | $30,22047 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $637 | $10,26718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Wildwood
- Lauren FalconerWildwood$10K
- Andrew BiondoKirkwood$300K
- John McGrealSaint Louis$126K
- Sarah HubbardChesterfield$91K
- Ariel CerenzieSaint Louis$76K
- Geoffrey PowellKansas City$55K
- Thomas HobbsSedalia$53K
- Heather WebsterColumbia$52K
- Sean MulqueenyCreve Coeur$45K
- Glen LojkaEllisville$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.